Olema Pharmaceuticals, Inc. Common Stock
OLMAOlema Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for women’s cancers. Founded to leverage innovative science, the company aims to address unmet medical needs in breast and ovarian cancers through novel approaches and personalized treatments.
Company News
Olema Oncology announced a clinical trial collaboration with Bayer to evaluate OP-3136, a KAT6 inhibitor, in combination with darolutamide in approximately 36 patients with metastatic castration-resistant prostate cancer. The Phase 1b/2 study is expected to initiate in H2 2026 and represents the first clinical collaboration for OP-3136. Olema wil...
Olema Oncology announced positive Phase 1 clinical data for OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities, manageable adverse events, and tumor shrinkage in over two-thirds of evaluable patients across multiple solid tumor types. The company plans to continue development as monotherapy and in combination with other agents includi...
The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market w...
Olema Oncology reported strong execution in 2025 with advanced enrollment in pivotal Phase 3 trials for palazestrant (OPERA-01 and OPERA-02) in ER+/HER2- metastatic breast cancer. The company initiated a Phase 1b/2 study with Pfizer's atirmociclib and expects top-line OPERA-01 data in fall 2026. Olema raised $218.5 million in gross proceeds from ...
The DJS Law Group is investigating Olema Pharmaceuticals (NASDAQ: OLMA) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered by an Investor's Business Daily report indicating that a failed Roche trial for an oral breast cancer medicat...
